Digest Network Come funziona
Network
/
Società
Ob
Non verificato

Obsidian Therapeutics, Inc.

Di cosa scriviamo

BiotecnologiaFarmaceuticaMedicina - VarieOncologiaSalute

8 comunicati stampa

Guarda tutti i comunicati
02/06/2025
Oncologia
Salute
Biotecnologia
Medicina - Varie
Farmaceutica
Eventi
Industria
Obsidian Therapeutics Announces Positive Clinical Data from OBX-115 in Patients with Advanced Melanoma in Ongoing Multicenter Study at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting
Fonte
Obsidian Therapeutics, Inc.
Emittente
Business Wire
1.00
0
28/04/2025
Eventi
Fiere
Industria
Salute
Biologia
Biotecnologia
Medicina - Varie
Farmaceutica
Obsidian Therapeutics to Present Preclinical Data Supporting Novel Application of cytoDRiVE® Platform at the American Society of Gene and Cell Therapy Annual Meeting
Fonte
Obsidian Therapeutics, Inc.
Emittente
Business Wire
1.00
0
25/04/2025
Eventi
Industria
Scienza
Biotecnologia
Farmaceutica
Oncologia
Salute
Igiene alimentare
Medicina - Varie
Obsidian Therapeutics Announces Multiple Presentations at the American Association for Cancer Research Annual Meeting
Fonte
Obsidian Therapeutics, Inc.
Emittente
Business Wire
1.00
0
23/04/2025
Industria
Scienza
Igiene alimentare
Medicina - Varie
Biotecnologia
Salute
Farmaceutica
Sanità
Oncologia
Obsidian Therapeutics to Present Clinical Data from OBX-115, its Engineered TIL Cell Therapy, for Patients with Advanced Melanoma in Oral Presentation at the 2025 ASCO Annual Meeting
Fonte
Obsidian Therapeutics, Inc.
Emittente
Business Wire
1.00
0
06/01/2025
Eventi
Scienza
Biotecnologia
Farmaceutica
Oncologia
Salute
Igiene alimentare
Medicina - Varie
Obsidian Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference
Fonte
Obsidian Therapeutics, Inc.
Emittente
Business Wire
1.00
0
05/11/2024
Fiere
Biotecnologia
Salute
Farmaceutica
Medicina - Varie
Oncologia
Obsidian Therapeutics to Present Preclinical Data Supporting OBX-115 and cytoDRiVE® Platform at the Society for Immunotherapy of Cancer (SITC) Annual Meeting 2024
Fonte
Obsidian Therapeutics, Inc.
Emittente
Business Wire
1.00
0
03/09/2024
Scienza
Biotecnologia
Oncologia
Sanità
Salute
Igiene alimentare
Industria
Obsidian Therapeutics Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for OBX-115 for the Treatment of Advanced Melanoma
Fonte
Obsidian Therapeutics, Inc.
Emittente
Business Wire
1.00
0
09/07/2024
Industria
Biotecnologia
Igiene alimentare
Sanità
Salute
Oncologia
Scienza
Medicina - Varie
Obsidian Therapeutics Announces FDA Fast Track Designation for OBX-115 for the Treatment of Advanced Melanoma
Fonte
Obsidian Therapeutics, Inc.
Emittente
Business Wire
1.00
0

Recapiti

Social Media

Seguaci
0
Compatibilità
0